Last reviewed · How we verify
VTAMA (tapinarof) cream, 1%
Tapinarof is an aryl hydrocarbon receptor (AhR) agonist that modulates immune responses in the skin to reduce inflammation and treat atopic dermatitis.
Tapinarof is an aryl hydrocarbon receptor (AhR) agonist that modulates immune responses in the skin to reduce inflammation and treat atopic dermatitis. Used for Atopic dermatitis (mild to moderate).
At a glance
| Generic name | VTAMA (tapinarof) cream, 1% |
|---|---|
| Also known as | DMVT-505 |
| Sponsor | Organon and Co |
| Drug class | Aryl hydrocarbon receptor (AhR) agonist |
| Target | Aryl hydrocarbon receptor (AhR) |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Immunology |
| Phase | FDA-approved |
Mechanism of action
Tapinarof activates the aryl hydrocarbon receptor, a nuclear receptor involved in immune homeostasis and barrier function. This activation promotes the differentiation of regulatory T cells and enhances skin barrier integrity, thereby reducing the inflammatory cascade characteristic of atopic dermatitis. The mechanism represents a novel approach distinct from traditional corticosteroids or calcineurin inhibitors.
Approved indications
- Atopic dermatitis (mild to moderate)
Common side effects
- Application site irritation
- Nasopharyngitis
- Headache
Key clinical trials
- Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis (PHASE3)
- A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region (PHASE4)
- A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis (PHASE4)
- Vtama in Psoriasis Patients Being Treated With Biologics. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |